Page 3 - Biocon

Karnataka CM's remark on Covid vaccines 'factually incorrect': Biocon chief

Biocon founder Kiran Mazumdar-Shaw on Thursday opposed Karnataka Chief Minister Siddaramaiah's remarks linking covid-19 vaccines with a spate of heart attack deaths in the state's Hassan district, saying such claims are "'factually incorrect" and "misleading". Siddaramaiah has suggested that the recent heart attack deaths in Hassan district may be linked to the vaccination drive. He had also claimed the vaccines were 'hastily' approved. In a social media post, Shaw said "covid-19 vaccines developed in India were approved under the Emergency Use Authorisation framework, following rigorous protocols aligned with global standards for safety and efficacy. To suggest that these vaccines were 'hastily' approved is factually incorrect and contributes to public misinformation." "These vaccines have saved millions of lives and, like all vaccines, may cause side effects in a very small number of individuals. It is important to acknowledge the science and data-driven processes behind their ...

Biocon climbs 3% on plans to file approvals for generic weight-loss drug

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of Novo Nordisk A/S's Ozempic and Wegovy

Biocon eyes early lead in generic Wegovy, Ozempic sales in Canada from 2026

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some emerging markets, its managing director, Siddharth Mittal said

Biocon Biologics to launch Eylea biosimilar Yesafili in Canada next month

Yesafili is the first Eylea biosimilar approved in Canada and Biocon Biologics' 10th commercialised biosimilar, with launch scheduled for July 4 across the country

Dividend stocks! M&M, 34 others to go ex-date next week; do you own any?

Container Corporation, and Paras Defence will also remain in focus, as the former has announced bonus issue of equity shares for its shareholders, while the latter has announced stock-split

Biocon's ₹4,500 crore equity raise to reduce debt by FY26, says S&P

S&P says Biocon will bring down adjusted debt to Rs 20,000 crore by FY26 through equity issuance, with strong cash flows aiding deleveraging and future capex needs

Decision on merger with Biocon Biologics soon, says Siddharth Mittal

We are talking about the GLP-1 opportunity and our strong franchise in insulins. There is a huge demand in the global diabetes-obesity segment, said Siddharth Mittal

Biocon closes ₹4,500 crore QIP to boost innovation, expand global access

Biocon raises ₹4,500 crore through QIP, its first equity issue since IPO, to fund innovation, repay debt, and expand global access to affordable biopharmaceuticals

Stocks to Watch today, June 17: NTPC, Vishal Mega Mart, Sona BLW, Zee Ent

Stocks to Watch today, June 17, 2025: Asian Paints, Sona BLW, Tanla Platforms, Mphasis are among shares to remain focus

Cordelia Cruise owner files DRHP, NSEIX inks MoU with CSE, and more

The International Finance Corporation (IFC), a member of the World Bank Group, has signed an agreement to invest $60 million in Motilal Oswal Alternates' India Business Excellence Fund V G

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon opens Rs 4,500-crore qualified institutional placement to repay debt, invest in Biocon Biologics and meet general corporate obligations

F&O picks: Biocon shows strength on charts, adopt Bull Spread: Nandish Shah

F&O strategy: Short-term trend of the Midcp Nifty turned weak, while it is strong for Biocon

Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'

Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes medication. The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (CDSCO). The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing. "The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said. India has one of the highest number of people with diabetes globally, with ...

Biocon share price pops 2% on CDSCO nod for diabetes drug; key details here

Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug, which is used in the treatment of type 2 diabetes.

Biocon share rises as arm secures UK MHRA nod for plaque psoriasis drug

Biocon share rose after arm, Biocon Biologics, was granted market authorisation in the UK for Yesintek, a biosimilar of Ustekinumab, from the Medicines and Healthcare products Regulatory Agency (MHRA)

Biocon Biologics gets six-month extension of insulin supply in Malaysia

Biocon Biologics to continue insulin supply in Malaysia through October 2025 as MoH extends existing contract under partnership with Duopharma and Biocon Sdn. Bhd.

Biocon shares gain 2% as Japan partner launches Ustekinumab biosimilar

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous Injection

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

Biocon Q4FY25 results: Consolidated net profit rises 153% to ₹344 crore

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ended March 31, 2025 aided by robust sales across business verticals. The company had reported a net profit of Rs 136 crore in the January-March period of the preceding fiscal. Total revenue rose to Rs 4,454 crore in the latest fourth quarter as compared to Rs 3,966 crore in the year-ago period, Biocon Ltd said in a statement. For the year ended March 31, 2025, the company said its net profit declined to Rs 1,013 crore as compared to Rs 1,022 crore in FY24, it added. Total revenue rose to Rs 16,470 crore in FY25 as compared to Rs 15,621 crore recorded in FY24, the company said. "The Biocon Group ended the year with a strong performance across its businesses," Biocon Group Chairperson Kiran Mazumdar-Shaw said. FY25 has been a year of consolidation and transition, she stated. "We are now on a path of accelerating growth with a commitment to innovation, digita